Check the Box Before Choosing Versa Lip Filler

“Versa lip filler” is not a precise product name. It often means Revanesse Versa+ used in the lips, but a clinic might mean Revanesse Lips+, Kiss+ or another market-specific Revanesse product. Before comparing a Tokyo quote, verify the exact box name, intended injection site, Japanese regulatory status, planned volume and emergency plan.

Select what the clinic has documented; the checker identifies what remains unresolved.

Versa+ and Lips+ Have Different US Labels

Revanesse Versa+ and Revanesse Lips+ are cross-linked hyaluronic acid gels made by Prollenium. The “+” denotes added lidocaine, a local anesthetic.

Under US labeling:

Product	FDA-Approved Purpose Relevant Here
Revanesse Versa+	Correction of moderate-to-severe facial wrinkles and folds, including nasolabial folds
Revanesse Lips+	Lip augmentation in adults aged 22 or older

The FDA approved the Lips+ lip-augmentation indication on September 21, 2020. Its professional instructions state that Lips+ and Versa+ are identical in formulation, but the products retain different names and labeled indications (FDA approval record; professional instructions).

The instructions also identify Revanesse Kiss+ as a lip product marketed outside the US and describe it as similar, but not identical, in composition. A clinic’s shorthand therefore cannot establish which filler it intends to inject. Ask to see the unopened box and syringe label. “FDA approved” is incomplete without the exact product, indication and jurisdiction.

The Lips+ Trial Supports a Specific US Indication

The pivotal US trial randomized 158 adults to Lips+ or another approved HA filler. It allowed an initial treatment and one optional touch-up approximately one month later. Follow-up was measured from the last treatment.

At month two, 49 of 54 Lips+ recipients in the per-protocol analysis—90.7%—had at least a one-grade improvement on the investigator-rated lip-fullness scale. The comparator result was 51 of 55, or 92.7%. The study met its primary objective by showing that Lips+ was not inferior to the comparator within the prespecified margin (FDA professional instructions).

Improvement was still measurable at month six in this per-protocol group: the average fullness score remained one grade above baseline. At that visit, 65% of participants rated themselves “much improved” or “very much improved,” while investigators assigned one of those ratings to 46%.

These results do not promise a personal six-, nine- or 12-month lifespan. Amount, placement, anatomy, lip movement and the point at which you notice fading can change the visible timeline. For maintenance planning, see how long lip fillers last.

The population also limits how precisely the findings apply to a Tokyo patient. Of the 158 participants, 156 were women and one was Asian. The trial supports the US label, but it cannot establish that one dose or injection pattern suits every face.

“Less Swelling” Is Not Established by the Label

Treat “minimal swelling” or “less swelling” as a marketing claim unless the clinic identifies the comparison and supporting evidence.

In the controlled trial, injection-site swelling was reported by 87.5% of Lips+ recipients and 89.7% of comparator recipients. Bruising occurred in 71.3% of the Lips+ group and injection-site pain in 21.3%. Most treatment-emergent events were mild or moderate, although some swelling, lumps and asymmetry lasted longer than 30 days.

These reporting rates do not mean every patient develops conspicuous swelling. They do show that “low swelling” should not be read as “no swelling.” The immediate post-injection appearance is not the settled result. See swelling and bruising after lip fillers for a practical recovery timeline.

Japanese Approval Must Be Checked Separately

US FDA approval does not establish Japanese approval. Japan’s Ministry of Health, Labour and Welfare warns that products used in elective aesthetic care may not have domestic approval and advises patients to understand what will be used, along with its safety and effectiveness, before treatment (MHLW cosmetic-medicine checklist).

For comparison, a PMDA record documents the October 2018 Japanese approval of Juvéderm Vista Volbella XC for purposes including lip augmentation (PMDA approved-device record). That does not make Volbella the right choice for a particular patient. It demonstrates why “HA filler” is not enough information.

If a Tokyo clinic proposes Revanesse, ask five product-specific questions:

1. What exact name and market appear on the box? Establish whether it is Lips+, Versa+, Kiss+ or another product.
2. Is that exact product approved in Japan for lip augmentation? If the clinic says yes, request the Japanese approval number and verify the indication rather than relying on overseas approval.
3. If it is imported, who imported it and through what route? MHLW says individually imported products have not received the same Japanese-law confirmation of quality, effectiveness and safety as products in authorized domestic distribution (MHLW import guidance).
4. Will the product sticker and lot number be added to the medical record? This preserves traceability if a reaction or recall occurs.
5. How much will be opened and injected, and what happens to the remainder? The answer should match the product’s packaging and single-use instructions.

The US Lips+ instructions describe a box containing two 1 mL single-use syringes. A Tokyo clinic may use different market packaging or sell treatment by a different unit, so confirm whether its quote is per syringe, per milliliter or per session.

No reliable Tokyo price figure is established by the cited evidence here. A meaningful comparison requires an itemized quote identifying the exact product, planned volume, consultation and anesthesia charges, tax, review appointment, touch-up policy and complication-care fees. A low session price is not directly comparable with a quote that includes a different volume or follow-up arrangement.

The Injector’s Emergency Plan Matters More Than the Brand

HA filler is temporary, but injection remains a medical procedure. Common effects include swelling, bruising, tenderness, redness and lumps. Infection, delayed inflammatory reactions and herpes reactivation can also occur.

The most concerning complication is unintended injection into a blood vessel, which can interrupt blood supply and cause tissue death, vision loss or stroke (FDA dermal-filler guidance). A product name does not show whether a clinic can recognize and manage that emergency.

Before consenting, ask the physician:

• Who will perform every injection, and what relevant training do they have?
• What is the response plan if vascular occlusion is suspected?
• Is hyaluronidase immediately available, and who can administer it?
• Who handles urgent concerns after hours?
• How do existing filler, asymmetry or a history of cold sores affect the plan?
• Do allergies, medicines, supplements, bleeding risks or recent dental and skin procedures require postponement or a different plan?

Do not stop a prescribed anticoagulant or antiplatelet medicine because of a generic cosmetic-treatment checklist. Discuss it with the clinician who prescribed it and the treating physician.

Seek immediate medical attention for unusual or escalating pain, white, gray or blue skin, vision changes, or stroke symptoms during or shortly after injection. These are not normal settling effects.

If fullness is simply uneven while swelling is evolving, do not massage or try to correct it unless the treating clinician specifically instructs you. Swelling and migration require different responses.

A defensible Versa lip-filler plan identifies the exact product and market, its intended placement and dose, its Japanese regulatory status, the complete price basis and the practitioner’s complication protocol. If the clinic will not document those points, its brand claims are not enough to support the decision.